Bridgeway Capital Management LLC Sells 280,200 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Bridgeway Capital Management LLC cut its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 90.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,000 shares of the biotechnology company’s stock after selling 280,200 shares during the period. Bridgeway Capital Management LLC’s holdings in Ironwood Pharmaceuticals were worth $137,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in IRWD. Renaissance Technologies LLC increased its stake in shares of Ironwood Pharmaceuticals by 5.5% in the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock worth $40,163,000 after purchasing an additional 469,043 shares during the period. Pacer Advisors Inc. increased its stake in shares of Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after purchasing an additional 450,949 shares during the period. Federated Hermes Inc. bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth about $1,641,000. Los Angeles Capital Management LLC increased its stake in shares of Ironwood Pharmaceuticals by 2,625.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company’s stock worth $1,469,000 after purchasing an additional 319,528 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Ironwood Pharmaceuticals by 107.0% in the fourth quarter. Walleye Capital LLC now owns 580,097 shares of the biotechnology company’s stock worth $2,570,000 after purchasing an additional 299,798 shares during the period.

Ironwood Pharmaceuticals Trading Down 6.8%

NASDAQ IRWD opened at $0.68 on Wednesday. The stock’s 50 day moving average is $1.12 and its two-hundred day moving average is $2.61. The company has a market capitalization of $110.71 million, a price-to-earnings ratio of -22.81 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.59 and a 1-year high of $7.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.09). The company had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. On average, analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Analysts Set New Price Targets

IRWD has been the topic of a number of recent analyst reports. Leerink Partners dropped their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating on the stock in a research note on Monday, April 14th. Wells Fargo & Company restated an “equal weight” rating and set a $1.00 price target (down from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Craig Hallum lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. Jefferies Financial Group restated a “hold” rating and set a $0.70 price target (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Finally, Citizens Jmp lowered Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 14th. Seven analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.78.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.